search proudct

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Nivolumab making it ideal for research use. This Nivolumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Nivolumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research use. This Bevacizumab biosimilar reacts with human VEGF (vascular endothelial growth factor). VEGF is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF biding to VEGF receptors has been the focus of several tumor therapeutic strategies. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the inhibition of tumor growth.

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Pembrolizumab making it ideal for research use. This Pembrolizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdcd1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1’s structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being used as cancer treatments. Pembrolizumab binds to PD-1 on activated immune cells to selectively block the interaction of PD-1 with its ligands.

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Infliximab making it ideal for research use. This Infliximab biosimilar reacts with human TNFα (tumor necrosis factor-alpha) a multifunctional proinflammatory cytokine. TNFα exists as a soluble 17 kDa monomer, which forms homotrimers in circulation or as a 26 kDa membrane-bound form. TNFα belongs to the TNF superfamily of cytokines and signals through its two receptors, TNFR1 and TNFR2 which can be activated by both the soluble trimeric and membrane-bound and forms of TNFα. TNFα is primarily produced by macrophages in response to foreign antigens such as bacteria (lipopolysaccharides), viruses, and parasites as well as mitogens and other cytokines but can also be expressed by monocytes, neutrophils, NK cells, CD4 T cells and some specialized dendritic cells. TNFα is known to play key roles in a wide spectrum of biological processes including immunoregulation, cell proliferation, differentiation, apoptosis, antitumor activity, inflammation, anorexia, cachexia, septic shock, hematopoiesis, and viral replication. TNFα dysregulation has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Infliximab blocks the interaction of TNFα with the TNFR1 (p55) and TNFR2 (p75) resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Atezolizumab making it ideal for research use. This Atezolizumab biosimilar reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. Atezolizumab blocks the interaction of PD-L1 with PD-1 and CD80.

人血清白蛋白(BSA),又称第五组分,是人血清中的一种球蛋白，可与多种阳离子、阴离子和其他小分子物质结合，白蛋白主要起维持渗透压作用、PH缓冲作用、载体作用和营养作用。
重组人血清白蛋白，更方便获取

用于过敏原检测、过敏反应研究以及相关产品的开发等领域。在过敏原检测中，可帮助确定个体是否对特定水果过敏；适用于免疫学方法主要包括发光、层析、ELISA、Western blotting和免疫印迹等技术，也可用于动物模型的制作。

用于过敏原检测、过敏反应研究以及相关产品的开发等领域。在过敏原检测中，可帮助确定个体是否对特定霉菌过敏；适用于免疫学方法主要包括发光、层析、ELISA、Western blotting和免疫印迹等技术，也可用于动物模型的制作。

我们提供草花粉和树花粉两大类过敏原提取液，用于过敏原检测、过敏反应研究以及相关产品的开发等领域。在过敏原检测中，可帮助确定个体是否对特定花粉过敏；适用于免疫学方法主要包括发光、层析、ELISA、Western blotting和免疫印迹等技术，也可用于动物模型的制作。

The 29F.1A12™ monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.

The 29F.1A12™ monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.

用于过敏原检测、过敏反应研究以及相关产品的开发等领域。在过敏原检测中，可帮助确定个体是否对特定动物皮屑过敏；适用于免疫学方法主要包括发光、层析、ELISA、Western blotting和免疫印迹等技术，也可用于动物模型的制作。

补体（C4）酶联免疫检测试剂盒是一款用于精准定量检测样本中补体 C4 含量的专业工具。该试剂盒基于酶联免疫吸附测定（ELISA）技术，利用抗原抗体特异性结合的原理，实现对目标物质的高效检测。试剂盒包含预包被 C4 抗体的反应板、标准品、生物素标记抗体等核心组分。使用时，将样本加入反应板，经孵育、洗涤、显色等步骤，通过酶标仪在特定波长下测定吸光度，结合标准曲线，即可准确计算出样本中 C4 的浓度。其具有灵敏度高、特异性强、重复性好等特点，广泛应用于医学研究等领域，为免疫系统相关疾病的诊断与病情监测提供重要依据。

人源蛋白（Hums 3）酶联免疫检测试剂盒是一款专注于精准测定样本中人源蛋白 Hums 3 含量的科研工具。该试剂盒基于酶联免疫吸附测定（ELISA）技术，利用抗原与抗体特异性结合原理，实现对目标蛋白的高灵敏度检测。试剂盒包含 Hums 3 抗体预包被板、标准抗原、生物素偶联抗体等核心组分。使用时，将样本加入预包被板，依次经孵育、洗涤、显色等步骤，通过酶标仪在 450nm 波长处测定吸光度，结合标准曲线即可计算 Hums 3 浓度。其具备检测快速、特异性强的优势，广泛应用于基础医学研究、蛋白功能探索等领域。

德国小蠊过敏原（Bla g 4）酶联免疫检测试剂盒是一款专业用于定量检测样本中 Bla g 4 含量的工具。它依托酶联免疫吸附测定技术，凭借抗原与抗体特异性结合的免疫学原理，实现精准检测。试剂盒配备 Bla g 4 抗体预包被板、标准抗原、生物素偶联抗体等关键组件。使用时，将样本添加至预包被板，依次进行孵育、洗涤、显色等操作流程，借助酶标仪在 450nm 波长下测量吸光度，再依据标准曲线得出 Bla g 4 的浓度。该试剂盒灵敏度高、特异性强，在过敏诊断和医学研究领域发挥重要作用，帮助人们判断自身对德国小蠊的过敏程度。